Score Card for American Oriental Bioengineering (AOBI)

 American Oriental Bioengineering
Shares Outstanding (MRQ): 78.18 mill
Fully diluted shares outstanding (most recent quarter, SEC filing)
POSITIVE: under 30 million shares  |  NEGATIVE: over 50 million shares
New Shares / Dilution (TTM): -11.28 mill-12.61%
Newly issued shares in the past 12 months (most recent quarter, SEC filing)
POSITIVE: under 10% dilution  |  NEGATIVE: over 30% dilution
Cash (MRQ): 111.43 mill28.51% 
Cash and cash equivalents, excl. restricted cash (most recent quarter, SEC filing)
POSITIVE: over 30% of market capitalization  |  NEGATIVE: under 10% of market capitalization
Account Receivables (MRQ): 46.87 mill11.99% 
Account/Trade receivables (most recent quarter, SEC filing)
POSITIVE: under 10% of market capitalization  |  NEGATIVE: over 30% of market capitalization
Account Receivables (Q/Q): -33.73 mill-41.85%
Quarterly increase/decrease of account/trade receivables (most recent quarter, SEC filing)
POSITIVE: quarterly decrease  |  NEGATIVE: quarterly increase of 20% or more
Relevant only if A/R to market capitalization ration higher than 10%
Long-Term Debt (MRQ): 136.87 mill35.02%
Long-term debt excl. warrant liabilities (most recent quarter, SEC filing)
POSITIVE: under 5% of market capitalization  |  NEGATIVE: over 20% of market capitalization
Revenue Growth (Q/Q): -37.62% 
Revenue Growth (Y/Y): -3.25%
Total revenue growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 30% revenue growth  |  NEGATIVE: negative revenue growth
Net Income Growth (Q/Q): -66.55% 
Net Income Growth (Y/Y): -70.41%
Net income growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 20% net income growth  |  NEGATIVE: negative net income growth
EPS Growth (Y/Y): -66.14%
EPS growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 10% EPS growth  |  NEGATIVE: negative EPS growth
EPS | P/E (2 MRQ Projection): $0.0953.01
Projected trailing annual EPS using the two most recently reported quarters
POSITIVE: P/E under 6 / 8 / 10  |  NEGATIVE: P/E over 12
CFPS | P/CF (2 MRQ Projection): $0.578.76
Projected trailing annual Operating Cash Flow per Share using the two most recently reported quarters
POSITIVE: P/CF under 6 / 8 / 10  |  NEGATIVE: P/CF over 12
Price/Sales (2 MRQ Projection): 1.44 
Projected trailing annual sales using the two most recently reported quarters
POSITIVE: Price/Sales ratio under 1.25  |  NEGATIVE: Price/Sales ratio over 2.5
Price/Book (MRQ): 0.90
Market capitalization / total stockholders' equity (most recent quarter, SEC filing)
POSITIVE: Price/Book ratio under 1.25  |  NEGATIVE: Price/Book ratio over 2.5
Recent High | Trading near Highs: $1.59214.46%
Difference between current price and recent (3-6 months) high
POSITIVE: current price within 20% of recent highs
Recent Low | Trading near Lows: $0.059,900.00% 
Difference between current price and recent (3-6 months) low
NEGATIVE: current price within 20% of recent lows
Forward EPS | P/E Projection (Estimates): $0.3514.29
Projected forward EPS (Trading China estimates)
POSITIVE: P/E under 4 / 6 / 8  |  NEGATIVE: P/E over 10
Auditor: Weinberg & Company
The Company's independent registered public accounting firm
POSITIVE: Top 10 ranked  |  NEGATIVE: not ranked in the Top 100
AOBI
Healthcare & Drugs
SCORE
-3
UNDER REVIEW
READ: Score Cards Explained
SAFETY/RISK SCORE
HIGH RISK
DETAILS: Safety/Risk Model for AOBI
Current Price:  $5.00
2008 Close: 566.66%$0.75
2009 Close: 7.52%$4.65
High (2012-03-14): 214.46%$1.59
Low (2012-07-13): 9,900.00%$0.05
Market Capitalization: 390.89 mill
Last Quarter: 2011-03-31
Revenue (MRQ): 52.00 mill
Net Income (MRQ): 0.92 mill
Op. Cash Flow (MRQ): 21.60 mill
all financial data provided without warranty